IBRX Stock Climbs Overnight: Founder Calls Sepsis Push 'Unstoppable' As Trials Near — Teases NantX After Crypto Heist

What happened

ImmunityBio shares climbed nearly 1% overnight before Tuesday. Founder Patrick Soon-Shiong said trials testing Anktiva in sepsis with persistent lymphopenia, a prolonged shortage of infection-fighting immune cells, will begin soon. Two Phase 2 studies are registered but not yet recruiting.

Confirmed

Global impact / market context

Sepsis would widen Anktiva beyond its approved bladder-cancer use, potentially adding a large new patient group and future revenue. Success could support the company's research spending and reduce reliance on one treatment area, while failure would leave the drug's commercial future concentrated in bladder cancer.

Analyst inference

The overnight gain follows a 4% fall to $7.95 on Monday, the third straight losing session. The founder's public comments and "NantX coming soon" teaser, after a crypto theft, are drawing attention, but the sepsis studies are not yet recruiting, so human testing has not started.

Analyst inference

What to watch

1. Watch whether the two registered Phase 2 sepsis studies, each about 50 patients and measuring deaths from any cause over 28 days, move from not yet recruiting to actively enrolling. Confirmed
2. Watch for details on the "NantX coming soon" plan the founder renewed after a crypto theft, including what the project is and how it relates to ImmunityBio. Proposed
3. Watch Anktiva's bladder-cancer expansion milestones, which could affect revenue and whether the company can fund sepsis research without raising outside money. Analyst inference

Evidence

• stocktwits.com